Inspire's therapy received FDA approval on August 27, 2025, and Rick Buchholz was serving as Chief Financial Officer.
2 reports, 1 independent
Updated Aug 27
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Inspire's therapy received FDA approval on August 27, 2025, and Rick Buchholz was serving as Chief Financial Officer.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Piper Sandler lowered its price target for Inspire after the company released its Q2 2025 financial results.Sub-event
- Inspire initiated the full launch of its neurostimulation system on August 8, 2025.Sub-event
Inspire secured FDA approval for its therapy, with Rick Buchholz as CFO.1 source
Keep exploring
The entities involved
Related events
- FDA approval enables commercial opportunity involving CBRE Group.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Experimental therapies require approval from the FDA.
- FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
Coverage
Newest first; wire copies grouped- GlobeNewswireInspire Medical Systems, Inc. Announces Departure of Chief Financial Officer MINNEAPOLIS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology
- GlobeNewswireInspire Medical Systems, Inc. to Present at the Wells Fargo 2025 Healthcare Conference MINNEAPOLIS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical t